Candidiasis intestinal

Candidiasis Intestinal tract, skin, mucous membranes (mouth, pharynx, vagina) Amphotericin B, fluconazole Caspofungin, flucytosine, itraconazole... 

Nystatin has a specific action on C. albicans and is of no value in the treatment of any other type of infection. It is poorly absorbed from the gastrointestinal tract even after very large doses, the blood level is insignificant. It is administered orally in the treatment of oral thrush and intestinal candidiasis infections. 

Q46 may be used in the treatment of intestinal candidiasis Q47 inhibits plaque formation on teeth Q48 may cause brov/n staining of teeth... 

Nystatin is a polyene antifungal, v/hich may be used orally for the treatment of intestinal candidiasis. 

It is used orally for intestinal candidiasis, topically for oral, vaginal and cutaneous candidiasis and hospital treatment of progressive and potentially fatal systemic fungal infections. It is the gold standard of antifungal therapy. Flucytosine has supraadditive action with amphotericin B if the fungi is sensitive to both. It is also potentiated by rifampicin and minocycline. 

Tetracyclines modify the normal flora, with suppression of susceptible coliform organisms and overgrowth of pseudomonas, proteus, staphylococci, resistant conforms, Clostridia, and Candida. This can result in intestinal functional disturbances, anal pruritus, vaginal or oral candidiasis, or enterocolitis with shock and death. 

Nystatin is a mixture of tetraene antifungals produced by cultures of Streptomyces noursei. The principal component is nystatin Ai (Figure 3.68), but the commercial material also contains nystatin A2 and A3, which have additional glycoside residues. Nystatin is too toxic for intravenous use, but has value for oral treatment of intestinal candidiasis, as lozenges for oral infections, and as creams for topical control of Candida species. 

Vaginal candidiasis is treated by clotrimazole, econazole, isoconazole, ketoconazole, miconazole or nystatin as pessaries or vaginal tablets or cream inserted once or twice a day with cream or ointment on surrounding skin. Failure may be due to a concurrent intestinal infection causing reinfection and nystatin tablets may be given by mouth... 

Concerning your question about the oral hydrogen peroxide, remember that Bigo did not start to improve at all until we gave him the oral peroxide to clear up his intestinal candidiasis. If a patient doesn t have oral thrush or any intestinal symptoms, certainly I agree that the oral peroxide is not necessary. But it is absolutely essential if they have any intestinal symptoms whatsoever. 

Nystatin (500,000 to 1,000,000 units three times daily) is indicated in the treatment of intestinal candidiasis. Nystatin, a polyene antibiotic with antifungal activity, is poorly absorbed from the gastrointestinal tract. It is both fungistatic... 

Cater, R. "Chronic Intestinal Candidiasis as a Possible Etiological Factor in chronic Fatigue Syndrome", Med. Hypotheses, 1995,44, 507-515. 

Fungi, such as Candida spp. (yeast), are normal flora of mouth, skin, intestine, and vagina. Candidiasis might be an opportunistic infection when the defense mechanisms are impaired. Antibiotics, oral contraceptives, and immunosuppressives may alter the body s defense mechanisms. Infections can be mild (vaginal yeast infection) or severe (systemic fungal infection). 

An in vitro study with amphotericin B found that it became markedly and irreversibly bound to sucralfate at the pH values found in the gut. This suggests that efficacy for intestinal candidiasis or gut decontamination might be decreased, but no study appears to have been conducted to establish this. 

It is not known how important this interaction is likely to be in practice, but the efficacy of amphotericin B for intestinal candidiasis or gut decontamination may be decreased. Separating the dosages might not be effective in some postoperative patients because their gastric function may not return to normal for up to 5 days, and some sucralfate might still be present when the next dose is given. This study was conducted more than a decade ago, and nobody appears to have conducted a clinical study to establish its hypothesis. If both sucralfate and oral amphotericin are required, it would seem prudent to monitor concurrent use carefully, being alert for any evidence of reduced effects. 

---